Similarly, several studies have evaluated the utility of CD81 and CD9 (together with CD45− and CD56+), for the discrimination between neuroblastoma cells and BM hematopoietic cells, for staging purposes [13], [48]–[49], [55], without extending such analysis to other subtypes of pediatric solid tumors. The gene discussed is CD9; the disease is neuroblastoma.